Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength.

Baud'huin M, Solban N, Cornwall-Brady M, Sako D, Kawamoto Y, Liharska K, Lath D, Bouxsein ML, Underwood KW, Ucran J, Kumar R, Pobre E, Grinberg A, Seehra J, Canalis E, Pearsall RS, Croucher PI.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12207-12. doi: 10.1073/pnas.1204929109. Epub 2012 Jul 3.

2.

Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R.

J Biol Chem. 2010 Jul 2;285(27):21037-48. doi: 10.1074/jbc.M110.114959. Epub 2010 Apr 12.

3.

ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.

Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R.

Mol Cancer Ther. 2010 Feb;9(2):379-88. doi: 10.1158/1535-7163.MCT-09-0650. Epub 2010 Feb 2.

4.

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7082-7. doi: 10.1073/pnas.0711263105. Epub 2008 May 6.

5.

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A.

Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14907-12. Epub 2004 Sep 29.

Supplemental Content

Support Center